Kura Oncology Reports Q1 2026 Results: Full Earnings Call Transcript

Kura Oncology (NASDAQ: KURA ) released first-quarter financial results and hosted an earnings call on Tuesday. Read the complete transcript below. This content is powered APIs. 8 million in net product revenue from the first full quarter of Comzifty's commercial launch, exceeding expectations.

Strategic focus is on expanding Ziftomenib across the AML treatment continuum and establishing it as a backbone therapy in combination treatments. Future guidance includes a steady flow of data over the next 12-24 months to support leadership in the Menin inhibitor class. Operational highlights include strong enrollment in the COMET-017 trials and significant progress in expanding the pipeline with additional combination data expected. Management highlighted the strong preparation, differentiated product profile, and experienced commercial team as key drivers of early success.

Full Transcript Layla, OPERATOR Good day everyone. My name is Layla and I will be your conference operator today. At this time I would like to welcome you to the Kura Oncology First Quarter 2026 Financial Results Earnings call. All lines have been placed on mute to prevent any background noise.

After the speaker's remarks, there will be a question and answer session. If you would like to ask a question during this time and if you have joined via the webinar, please use the raise hand icon which can be found at the bottom of your webinar application. To allow everyone the opportunity to participate, we ask that you please limit yourself to one question and then re-enter the queue. Any follow-ups?

At this time I would like to turn the call over to Greg Mann, SVP of Investor Relations and Corporate Affairs of Kura Oncology. Please go ahead. Greg Mann, Senior Vice President, Investor Relations & Corporate Affairs Thank you, Layla. Good afternoon and welcome to Kura Oncology's first quarter 2026 conference call.

Joining the call today are Dr. Troy Wilson, President and Chief Executive Officer; Brian Powell, Chief Commercial Officer; Dr. Molly Leone, Chief Medical Officer; and Tom Doyle, Senior Vice President, Finance and Accounting. We remind you that today's discussion will include forward-looking statements based on current expectations.

Such statements represent management's judgment as of today and may involve risks and uncertainties that cause actual results to differ materially from expected results. Please refer to Kura's filings with the SEC, which are available from the SEC or on the Kura Oncology website for information concerning risk factors that could affect the company. With that, I'll turn the call over to Troy. Troy Wilson, President, Chief Executive Officer and Chairman of the Board Thank you, Greg.

Good afternoon everyone. Kura is at an inflection point. What we've been building over the last several years is now showing up clearly in the clinic, in the market, and in the way physicians are making treatment decisions. Our first commercial launch is off to a strong start.

Our phase three programs are ahead of plan and over the next 12 to 24 months we expect a steady flow of data that we believe will define leadership in the Menin inhibitor class. Most importantly, we're executing with focus, discipline, and a very clear strategy. Let me start with Comsifty. 8 million in net product revenue ahead of expectations.

But what matters more to us is what's underneath those numbers. We're seeing repeat prescriptions. We're seeing broad uptake and use expand across treatment centers. We're seeing increasing payer preference and we're seeing early instances of physicians switching patients from other Menin inhibitors to Comsifty.

That tells us something important. This is not just a class story anymore. Physicians are starting to differentiate based on product profile, and we believe Comsifty is standing out. We see that differentiation coming from a combination of compelling efficacy, a predictable safety profile, simple and convenient dosing, and potential for broad combinability in real-world practice.

These things matter, and they're driving how physicians choose therapy. It's early, but based on what we're seeing, we believe Comsifty is well positioned to emerge as a leader in the treatment of adult patients with relapsed refractory NPM1 mutant AML. At the same time, we're not building this as a single indication product. Our focus is to expand Ziftamentib across the AML treatment continuum and establish it as a backbone therapy in combination.

This year we expect to generate multiple data readouts to support that strategy, including updated data from our 7+3 combination in newly diagnosed AML at EHA, publication of our Venetoclax Azacytidine combination, and initial data from our Gilteritinib combination in relapsed and refractory AML patients with NPM1 and FLT3 mutations. Taken together, these data sets are designed to answer a simple question: can Comsifty be used broadly, safely, and effectively in combination across AML? Based on what we've seen so far, we believe the answer will be yes.

In parallel, our frontline phase three program, Comet 017, is progressing ahead of plan with strong enrollment for both studies across leading global sites. Our one-stop-shop design is doing exactly what we intended, accelerating execution without compromising rigor. Beyond AML, we continue to build a broader pipeline with meaningful upside. Darla Farnab is a good example.

The data we've generated reinforce its mechanism and potential to overcome resistance to targeted therapies. We'll have additional combination data this year, including in KRAS G12C mutated cancers where we think there's an opportunity to open up new treatment approaches across large solid tumor indication